A Clinical Study to Evaluate the Safety, Tolerability, PK, PD, and Efficacy of KBP-089 in Patients With T2DM

PHASE1

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped The trial was planned to be conducted in 4 cohorts but was terminated after completion of Cohort 2 for strategic reasons due to limited PD effects.

Conditions

Type II Diabetes Mellitus

Interventions

DRUG: Daily injection of KBP/placebo for up to 28 days

Sponsor

KeyBioscience AG

Collaborators

[object Object]
[object Object]
[object Object]